Identification of B(A) Blood Group Serology Combined with Molecular Biology and Blood Transfusion Strategy.
10.19746/j.cnki.issn.1009-2137.2022.06.034
- Author:
Wen-Gang ZHU
1
;
Gui-Bin YANG
2
;
Yin-Yin LIU
2
;
Lei LIU
2
;
Bang-Kun XIA
2
Author Information
1. Department of Blood Transfusion, Fuyang People's Hospital, Fuyang 236006, Anhui Province, China,E-mail: 32895843@qq.com.
2. Department of Blood Transfusion, Fuyang People's Hospital, Fuyang 236006, Anhui Province, China.
- Publication Type:Journal Article
- Keywords:
ABO blood group;
B(A) subtype;
blood group identification;
blood transfusion;
molecular biology identification
- MeSH:
Humans;
Aged;
ABO Blood-Group System/genetics*;
Molecular Biology;
Siblings;
Blood Transfusion
- From:
Journal of Experimental Hematology
2022;30(6):1845-1850
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the reasons for ABO blood group forward typing and reverse typing incompatibility of the proband by serological and molecular biological tests, so as to clarify the blood group and genetic rules and determine the reasonable transfusion strategy.
METHODS:On the basis of serological testing results, PCR-SSP method was utilized for the ABO exon sequencing in the peripheral blood of the proband and 5 family members, and blood group results were comprehensively analyzed.
RESULTS:The serological results of ABO blood group of the proband were incompatibility, and the molecular biological test results showed that there was a c.700C>G mutation compared with B101, which was consistent with B(A)02 subtype, and the genotype was B(A)02/O02. The results of the elder brother was the same as the proband. The nephew of the proband also detected c.700C>G, genotype A102/B(A) 02.
CONCLUSION:When the result of standard serological test for ABO blood group incompatibility occurs, using molecular biology detection technology to explore mutation is an effective method to confirm ABO subtype, and ensures the safety of clinical blood transfusion.
